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Abstract
In this chapter, we are going to discuss about salivary glands cancers, their clinical man-
ifestations and categories, pathogenesis, diagnosis and treatment. We will go through 
details in each part in both clinical and surgical aspects based on recently prominent 
published studies and research in prestigious journals. After a short review on clinical 
features, epidemiology, pathogenesis, diagnosis and treatment, we will show staging 
and tumor node metastasis (TNM) classification of major salivary gland tumors and also 
basic principles of approach to salivary gland cancers. A little will be explained about 
basic surgical procedures for removal of cancers and benign tumors.
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1. Embryology, anatomy and structure of salivary glands
There are three pairs of salivary glands in human: parotid (PG), submandibular (SMG) and 
sublingual gland (SLG). They all have the same architecture; an arborized duct which opens 
into the oral cavity with secretary end pieces called acini which produce the saliva [1]. A 
mixed structure of extracellular matrix, myoepithelial cells, myofibroblasts, immune cells, 
endothelial cells, stromal cells, and nerve fibers surround the acinar cells. The main excre-
tory duct of PG is Stensen’s duct which opens in buccal mucosa near the second maxillary 
molar after crossing the masseter muscle and penetrating buccinators muscle. Submandibular 
glands secrete the saliva through their main excretory duct, called Wharton’s, which opens 
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into the oral cavity under the tongue by the lingual frenum at a structure called the sublingual 
caruncule. In contrast, sublingual gland has small ducts called ducts of Rivinus and a common 
duct, Bartholin’s duct, which connects with Wharton’s duct at the sublingual caruncle [1].
Blood supply of parotid gland is mainly provided by the transverse facial artery and SMG 
by the facial artery. Postganglionic nerves from the otic and submandibular ganglia provide 
parasympathetic innervation. Superior cervical ganglion makes sympathetic postganglionic 
nerves which innervate the glands along blood vessels [1, 2]. Facial nerve is closely associated 
with PG capsule and facial nerve injury resulting in hemifacial paralysis is a major complica-
tion of parotid gland surgery. Lingual nerve accompanies Wharton’s duct and then lingual 
nerve injury may be a complication of surgical exploration of floor of mouth for salivary 
stones removal.
Major salivary glands produce over 90% of saliva in a healthy adult. Saliva excretion is stim-
ulated by both parasympathetic and sympathetic autonomic nervous system necessary for 
lubricating the oral cavity to enable eating, talking, swallowing, dental health and maintain-
ing oral homeostasis, tasting, while also providing protective functions and aiding in diges-
tion. Different types of saliva are produced by two types of acinar cells. Parotid gland secretes 
watery serous saliva produced by serous acini. SMGs and SLGs contain both serous and 
mucous acinar cells. Most of the acinar cells in SMGs are serous, while the majority of SLG 
is composed by mucous acinar cells. In addition to major salivary glands, there are several 
minor glands which are widely distributed across the oral mucosa [3].
Major salivary glands start to develop at 6–8 weeks of gestation. Oral ectoderm starts thicken-
ing to produce placodes of major glands. Growth factors and other necessary molecular cues 
for epithelial branching morphogenesis are provided by neural crest-derived mesenchyme. 
SMGs seem well differentiated with desmosomes and microvilli projected from cells along 
lumens by 13–16 weeks of gestation. At 16 weeks, the striated and intercalated ducts can be 
recognized and acinar cells begin to predominate tissue by 20–24 weeks [4]. Salivary glands 
continue to develop up to 28 weeks and glands can secret saliva at birth.
2. Salivary gland neoplasms
Salivary gland tumors are a diverse group of neoplasms in terms of both morphology and 
clinical manifestations. These tumors have an incidence of approximately 2.5 cases to 3.0 cases 
per 100,000 per year [5]. Salivary gland malignancies consist more than 0.5% of all malignan-
cies and approximately 3–5% of all head and neck cancers [6]. Salivary gland tumors usually 
involve people in their sixth or seventh decade of life [7, 8]. Recent studies have indicated that 
incidence of major salivary glands are increasing [9].
The exact etiology of salivary gland malignancies has not been determined; however ionizing 
radiation is indicated as a cause of salivary gland cancer [6, 7, 10, 11].
Tumors of salivary gland are related to both major and minor salivary glands. Minor salivary 
gland lesions are more frequently seen in palate; however, they can be found throughout 
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oral cavity as oral mucosa, posterior tongue, larynx, pharynx, paranasal sinuses, retromolar 
and peritonsillar areas, uvula and floor of mouth [6, 12]. More than 50% of salivary gland 
tumors are benign and about 70–80% of all salivary gland neoplasms originate from parotid 
gland [13]. Different sites have different rate of malignancy so that 20–25% of parotid, 
35–40% of submandibular, 50% of palate and more than 90% of sublingual gland tumors 
are malignant [14].
Comprising about 50% of all salivary gland tumors and 65% of parotid gland tumors, pleo-
morphic adenoma is the most common benign minor and major salivary gland tumor. On 
the other hand, mucoepidermoid carcinoma is the most prevalent major and minor salivary 
gland tumor comprising 10% of all salivary gland and about 35% of malignant salivary neo-
plasms [15]. This neoplasm mostly occurs in parotid gland [15, 16].
Most benign major and minor salivary gland tumors present with painless swelling of the 
parotid, submandibular or sublingual glands. Numbness or weakness which are signs of 
nerve involvement, typically indicate malignancy. Facial nerve weakness accompanied by 
parotid tumor is not a pleasant sign. A majority of benign and malignant tumors of parotid 
gland present as asymptomatic mass in the gland [13].
Tumors have more favorable prognosis when present in major salivary glands; parotid gland 
tumors have the best prognosis followed by submandibular gland. On the other hand, sub-
lingual and minor salivary gland tumors have less favorable prognosis. Adequate surgical 
resection is enough for curing early-stage low-grade major and minor salivary gland tumors. 
In contrary, high-grade tumors have poorer prognosis and may need postoperative radia-
tion therapy [17]. In addition, histology, grade, extent of primary tumor (stage), facial nerve 
involvement, fixation to skin or deep structures and lymph node or distant metastasis are 
among other factors involved in prognosis [18, 19].
3. Classification of tumors
Several pathological classifications have been proposed for salivary gland tumors since 50 
years by several authorities such as Armed Forces Institute of Pathology and the World Health 
Organization (WHO). In 1954, there were only 16 salivary gland epithelial tumor entities in 
pathological classification which increased to 36 entities in 1996 showing an evident progress 
[20]. Table 1 shows WHO histological classification of epithelial tumors of the salivary glands.
3.1. Acinic cell carcinoma
Acinic cell carcinoma (AcCC) comprises one of six parotid cancers which is supported by a 
nationwide study in the Netherlands where 15% of parotid malignancies were AcCC [21–23]. 
Based on 1973–2009 Surveillance, Epidemiology, and End Results (SEER) analysis AcCC com-
prises 11% of salivary malignancies [24]. AcCC has an average annual incidence of 0.13 cases 
per 100,000 patients per year. Also approved by other studies, SEER program indicated that 
AcCC has a higher average incidence for females than males (0.15 cases vs. 0.11 cases per 
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Malignant epithelial (n = 24)
Acinic cell carcinoma
Oncocytic carcinoma
Mucoepidermoid carcinoma
Salivary duct carcinoma
Adenoid cystic carcinoma
Adenocarcinoma (NOS)
Polymorphous (LG)
Adenocarcinoma
Myoepithelial carcinoma
Epithelial-myoepithelial carcinoma
Carcinoma ex pleomorphic adenoma
Clear cell carcinoma (NOS)
Carcinosarcoma
Basal cell adenocarcinoma
Metastasising pleomorphic adenoma
Sebaceous carcinoma
Squamous cell carcinoma
Sebaceous lymphadenocarcinoma
Small-cell carcinoma
Cystadenocarcinoma
Large cell carcinoma
LG cribriform cystadenocarcinoma
Lymphoepithelial carcinoma
Mucinous adenocarcinoma
Sialoblastoma
Benign epithelial (n = 10)
Pleomorphic adenoma
Lymphadenoma
 Sebaceous
 Nonsebaceous
Ductal papilloma
 Inverted ductal papilloma
 Intraductal papilloma
 Sialadenoma papilliferum
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100,000 patients) [25, 26]. Patients with AcCC have a median age of 52 years at the time of 
diagnosis and it occurs more in younger ages than other salivary gland tumors [27]. One-third 
of patients are under 40, one-third between 40 and 59 and one-third above 60 years of age [24]. 
AcCC more frequently occurs in whites (85%) than in blacks (7%) or other races (8%) [24, 28]. 
There are no known risk factors for AcCC; however, family history and radiation exposure 
have been proposed as potential risk factors [29].
The most common clinical feature of AcCC is a slow-growing swelling and its association 
with pain or fixation to neighboring structures is an indicator of poor prognosis [25]. Nodal 
metastasis is really uncommon at the time of diagnosis [26]. AcCC is less common in minor 
salivary glands and comprises only 9% according to SEER database [30]. AcCC of minor sali-
vary glands mostly occur in buccal mucosa and upper lip in contrast to other types of minor 
salivary glands which mostly occur in palate [31, 32].
3.1.1. Diagnosis and preoperative assessment
Since AcCC often presents symptomless, preoperative assessment seems necessary to deter-
mine location of tumor, extent and malignancy indicators as in parotid surgery these factors 
show the risk of facial nerve injury [33]. Imaging is highly suggested when a glandular swell-
ing is accompanied by impaired mobility or when involvement of deeper structures or nerves 
is suspected [34–37].
Imaging modalities include ultrasound (US), computed tomography (CT), magnetic resonance 
imaging (MRI) and positron emission tomography (PET) [33]. AcCC is appeared defined, lob-
ular, hypoechoic, heterogeneous and poorly vascularized; while on CT, it is appeared regular 
and variably defined with heterogeneous enhancement [38].
MRI is preferred to CT for assessment of parotid, stylomastoid foramen and neural or peri-
neural invasion [35, 37, 39, 40]. However, it is a rare condition; PET scan is indicated only 
when there is a high suspicion of distant metastatic disease. Also it is indicated postopera-
tively in case of AcCC with high-grade transformation [33, 41–43]. Ultrasound-guided fine 
needle aspiration cytology (FNAC) and ultrasound-guided core biopsy (USCB) are needling 
procedures for diagnosing AcCC [22, 44].
Myoepithelioma
Basal cell adenoma
Warthin tumor
Oncocytoma
Canalicular adenoma
Sebaceous adenoma
Cystadenoma
Table 1. WHO (2005) histological classification of epithelial tumors of the salivary glands, squamous cell carcinoma 
(SCC) and tumors like “carcinoma in pleomorphic adenoma”.
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3.1.2. Management
The main treatment for AcCC is surgical resection, as AcCC do not show distant metastasis at 
the time of diagnosis and is usually an accessible tumor [25, 33]. For low-grade AcCC, surgery 
alone may be curative; while for known high-grade tumors in risk of positive margins, bone 
or nerve invasion and nodal metastasis a more aggressive approach is needed. A preopera-
tively paralyzed or involved facial nerve should be resected and repaired by interposition 
graft from greater auricular or sural nerve [22]. Elective neck dissection is not recommended; 
nevertheless patients with large or high-grade tumors may benefit from level II, III and IV 
neck dissections [26].
Radiotherapy is not necessary for low grade, low stage and adequately resected AcCCs [45]. 
As like other salivary gland cancers, criteria for radiotherapy include recurrent disease, 
advanced T-classification (T3/T4), positive margins, pathologically positive cervical lymph 
nodes, perineural invasion, high-grade and high proliferative tumors [24, 26, 28].
Role of chemotherapy is not exactly known in treatment of AcCCs; however, mTOR inhibitors 
may be beneficial [22].
3.2. Mucoepidermoid carcinoma
Defined as “a malignant glandular epithelial neoplasm characterised by mucous, intermedi-
ate and epidermoid cells, with columnar, clear cell and oncocytoid features” by World Health 
Organization (WHO), mucoepidermoid carcinoma (MEC) was first described by Masson and 
Berger [46–48]. MEC is considered as the most common primary salivary gland malignancy 
and patients have a mean age of 45 years old at the time of diagnosis [49, 50]. Children are 
rarely involved and gender differences are not marked [51, 52].
Parotid is the most commonly involved major salivary gland and MEC of minor salivary 
glands is usually found on the palate followed by buccal mucosa, tongue, lips and floor of 
mouth [51]. Another important location is retromolar area in which 18% of intra-oral MECs 
can be detected [53]. MEC may also be rose from salivary-type glands in sinonasal and laryn-
geal mucosa lachrymal and ceruminous glands, and even nodal glandular inclusions [54–57].
The most common clinical manifestation of MEC is a painless, variously fixed, rubbery or soft 
mass. Intra-oral tumors may appear as a blue-red tinged swelling which mimics a mucocele 
or vascular tumor because of their superficial location [51, 53]. The interval between initial 
symptoms and diagnosis differs depending on the site of origin [16]. Sublingual MEC is pain-
ful and patients are usually diagnosed earlier than parotid or submandibular tumors [16].
3.2.1. Preoperative assessment
Imaging is less necessary for diagnosing MECs unless they are located on the palate or ret-
romolar area of mandible or involvement of deeper structures or cranial nerves is suspected 
[46]. CT scan is beneficiary for assessment of bone invasion by the tumor; while MRI is bet-
ter for soft tissue. Ultrasound (US) may be satisfactory if small tumors are located in major 
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salivary glands; for larger tumors or tumors outside these glands, a combination of CT and 
MRI is suggested. According to recent studies, positron emission tomography (PET) has been 
beneficial in loco-regionally advanced tumors [58]. Fine needle aspiration biopsy (FNAB) is 
another preoperative diagnostic modality which is dependent on expertise of pathologist and 
number of patients treated in the institute [59].
3.2.2. Management
Complete surgical removal of tumor is the treatment of choice in case of anatomically acces-
sible MECs [32]. More treatment planning is needed when MECs are locally advanced, incom-
pletely resected or with positive margins, invaded to bone or nerves, metastasized to lymph 
nodes or high grade [18, 60].
For low-grade tumors, surgery alone is curative; however, site and size of tumor influence the 
extent of surgery. For parotid, superficial parotidectomy is enough unless the tumor involves 
deep lobe [61]. Resection of facial nerve is recommended if there is preoperative facial nerve 
paralysis or weakness or there is evidence of perineural invasion in frozen section [46]. If 
submandibular or sublingual glands are involved, resection of the anterior mandible or mylo-
hyoid muscle should be considered. Wide local excision is usually curative if minor salivary 
glands are involved with low-grade small MECs. Mandibulectomy, maxillectomy, mastoid-
ectomy, infratemporal fossa, anterior craniofacial resection, soft or hard palate resection or 
resection of cranial nerves may be required in more extensive disease [62]. For tumors in 
tonsillar area, radical tonsillectomy and ipsilateral neck dissection is applied [32, 63]. Elective 
neck dissection should be done in high-grade MEC and avoided in low- or intermediate-
grade tumors [32].
Radiotherapy is recommended for high-grade MECs and patients with perineural invasion, 
positive margins and T3–4 classification [64, 65]. For patients with increased risk of nodal 
metastasis, elective neck irradiation may be applicable [32, 66]. The role of chemotherapy is 
not approved in the treatment of MECs and some clinical trials are being conducted regard-
ing this issue.
3.3. Adenoid cystic carcinoma (cylindroma)
Accounting for about 1% of all head and neck cancers and 10% of all salivary gland tumors, 
adenoid cystic carcinoma (AdCC) is a rare tumor with a yearly incidence of about 3–4.5 cases 
per million [67–70]. On the other hand, it is the most common malignancy of minor salivary 
gland tumors with a proportion ranging from 32 to 71% [67]. AdCC may involve other sites 
and glands such as lacrimal and ceruminous glands as well as nasal and paranasal sinuses, 
larynx and trachea [32, 67, 71–74]. AdCC is mostly found in the parotid, submandibular and 
minor salivary glands. Based on previous studies, AdCC was the most frequent histology of 
parotid carcinoma [23]. In the submandibular gland, the likelihood of AdCC is even greater 
as it accounts for 40% of salivary gland cancers [75, 76]. AdCC of minor salivary glands is 
most frequently found in the palate followed by paranasal sinuses and other parts of salivary 
glands [32, 77].
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Although more prevalent in middle-aged and older patients in fifth and sixth decades of life, 
AdCC occurs in all age groups [12, 78–81]. Until now, there are no known risk factors for 
AdCC and smoking has not been proven to affect incidence [82].
The characteristic cribriform arrangement of tumor cells on microscopy and invasion to sur-
rounding structures and nerves were first described in 1853 and 1854 by Robin, Lorain and 
Laboulbene [83].
AdCC is a really invasive tumor which is recognized by perineural invasion and multiple 
local recurrences. Although considered rarely, but regional lymph node metastasis may be 
hidden according to its occult and clinically undetectable nature and lack of pathological 
assessment of lymph nodes. Hematogenous metastasis is also common especially to lung, 
bone and liver [83, 84].
As one of the most biologically destructive and unpredictable tumors of the head and neck, the 
most common clinical manifestation of AdCC is a slowly growing mass followed by pain. AdCC 
symptoms vary according to the site of disease. The tumor usually presents with a mass in major 
salivary glands and may lead to facial nerve paralysis when located in parotid [69, 85]. When 
located in the palate, a mass is common; however, ulcer or even oroantral fistula may be detected. 
Dyspnea is the first symptom in larynx and nasal obstruction, epistaxis, eye symptoms and deep 
facial pain are presenting symptoms of nose and paranasal sinuses involvement [32, 86, 87].
3.3.1. Preoperative assessment
As other salivary gland malignancies, preoperative imaging of AdCC includes computed 
tomography (CT) and magnetic resonance imaging (MRI) which help with estimation of dis-
ease extent. CT scan is preferred for bone invasion assessment and MRI is more appropri-
ate for evaluation of soft tissue extension or suspected neural invasion presenting as pain or 
facial nerve analysis [88]. Positron emission tomography (PET) scan in combination with CT 
is applied for excluding distant metastasis [89].
3.3.2. Management
Decision-making for treatment of AdCC depends on tumor location, stage at diagnosis and 
biologic behavior of tumor reflected in histologic grading [90]. Radical surgical resection of 
tumor, ensuring free margins, followed by postoperative radiotherapy is the gold-standard 
treatment for AdCC. Since AdCC has a high potential for infiltrating to neighboring tissue, 
mainly by perineural invasion, the free margin may not be reached. In anatomical sites with 
difficult access, incomplete resection has remained as a problem.
In case of parotid involvement, facial nerve should be preserved if it is not paralyzed preop-
eratively and not involved by tumor at the time of surgery. Radiotherapy after surgery is con-
sidered as an appropriate adjuvant therapy for possible residual tumors on nerve branches 
[45, 91, 92].
Neck dissection is only performed in patients with clinically positive lymph nodes; however, 
it is not common in AdCC especially for parotid malignancies [93]. The number of involved 
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lymph nodes is higher in minor salivary glands AdCC. Lymph nodes could also be involved 
by direct extension of primary tumor when AdCC is located in parotid, submandibular 
gland and larynx [94, 95]. Despite combination therapy with surgery and radiotherapy, local 
recurrence happens [69]. Chemoradiotherapy may be considered using various agents in 
patients with adverse prognostic factors [96]. To the best of scientists’ knowledge, patients 
with locally recurrent or metastatic AdCC may not experience cure by systemic treatment 
using cytotoxic chemotherapy or targeted molecular therapies [69]. So chemotherapy may be 
considered as a palliative treatment for patients with poorly-controlled disease or symptom-
atic metastasis [97].
3.4. Basal cell adenocarcinoma
Basal cell adenocarcinoma (BCAC) occurs equally in both genders and usually involves 
patients in fifth or sixth decades of their lives [98]. In the setting of syndromic disease, it 
may have multifocal lesions of multiple cylindromatosis and trichoepitheliomas (Brooke-
Spiegler syndrome) [99]. Basal cell adenocarcinoma usually has an indolent behavior but may 
be locally aggressive and one-third of cases experience recurrence. It has been reported that 
BCACs have a regional and distant metastatic rates ranging from 8 to 12% and 2 to 4%, respec-
tively [100, 101]. The main treatment strategy for basal cell adenocarcinoma is surgery with 
lymph node dissection, if required. High-stage tumors are treated with radiotherapy which 
may improve outcome [101].
3.5. Epithelial-myoepithelial carcinoma
As a biphasic salivary gland malignancy, epithelial-myoepithelial carcinoma (EMCA) may 
occur at any sites containing salivary or seromucinous glands [98]. It is mostly (60–80%) 
prevalent in parotid glands and involves people in sixth decade of life. Female-male ratio 
is 3:2 [102]. RAS mutation is detected in 20 to 25% of cases with predominancy of HRAS 
codon 61 mutations [103]. EMCA is typically a low-grade tumor and has an estimated 5-year 
disease-specific survival (DSS) of 90–95% and 10-year DSS of 80–90% [102, 104]. Often late, but 
about one-third of patients experience recurrence with a median disease-free survival (DFS) 
of 11 years. Regional and distant metastases are uncommon [104]. Factors like margin status, 
vascular invasion, necrosis, and high-grade features are among important prognostic factors 
[102]. EMCA is surgically treated with no sensible effect of radiotherapy [102, 104].
3.6. Mammary analogue secretory carcinoma, a new entity
Mammary analogue secretory carcinoma (MASC) is a newly defined salivary gland malig-
nancy based on morphologic and molecular features [44, 105]. Previously, most of MASC 
were marked as acinic cell carcinoma or adenocarcinoma not otherwise specified [98]. Both 
genders are equally involved and MASC typically occurs in fifth to sixth decades of life.
There are limited data on management of MASC; it may have a higher rate of lymph node 
metastasis (up to 25%) than acinic cell carcinoma [106]. Nonetheless, surgery is the main treat-
ment for MASC.
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4. TNM classification and staging of major salivary gland tumors
The most common system for cancers in the major salivary glands is the TNM system of the 
American Joint Committee on Cancer (AJCC), available at (https://www.cancer.org/cancer/
salivary-gland-cancer/detection-diagnosis-staging/staging.html).
T groups for major salivary gland cancers:
TX: The main (primary) tumor cannot be assessed; information not known.
T0: No evidence of a primary tumor. (For example, the cancer was first found in the lymph 
nodes, but the main tumor itself can’t be found.)
T1: Tumor is 2 cm (about ¾ inch) across or smaller. It’s not growing into nearby tissues.
T2: Tumor is larger than 2 cm but no larger than 4 cm (about 1½ inch) across. It is not growing 
into nearby tissues.
T3: Tumor is larger than 4 cm across and/or is growing into nearby soft tissues.
T4a: Tumor is any size and is growing into nearby structures such as the jaw bone, skin, ear 
canal, and/or facial nerve. This is known as moderately advanced disease.
T4b: Tumor is any size and is growing into nearby structures such as the base of the skull or 
other bones nearby, or it surrounds the carotid artery. This is known as very advanced disease.
N groups for major salivary gland cancers:
NX: Nearby (regional) lymph nodes cannot be assessed; information not known.
N0: No spread to regional lymph nodes.
N1: The cancer has spread to one lymph node on the same side of the head or neck as the 
primary tumor. The lymph node is no larger than 3 cm (about 1¼ inch) across.
N2: This group includes 3 subgroups:
• N2a: The cancer has spread to one lymph node on the same side as the primary tumor. 
The lymph node is larger than 3 cm but not larger than 6 cm (about 2½ inches) across.
• N2b: The cancer has spread to more than one lymph node on the same side as the 
primary tumor, but none of the lymph nodes are larger than 6 cm across.
• N2c: The cancer has spread to one or more lymph nodes, none larger than 6 cm across, 
either on the side opposite the primary tumor or on both sides of the neck.
N3: The cancer has spread to a lymph node that is larger than 6 cm across.
M groups for major salivary gland cancers:
M0: The cancer has not spread to tissues or organs far away from the salivary glands.
M1: The cancer has spread to tissues or organs far away from the salivary glands.
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Stage grouping:
Stage I: T1, N0, M0: The tumor is no more than 2 cm across and is not growing into nearby 
tissues (T1). It has not spread to nearby lymph nodes (N0) or distant sites (M0).
Stage II: T2, N0, M0: The tumor is larger than 2 cm but is no larger than 4 cm across and is 
not growing into nearby tissues (T2). It has not spread to nearby lymph nodes (N0) or distant 
sites (M0).
Stage III: Either of the following:
T3, N0, M0: The tumor is larger than 4 cm across and/or is growing into nearby soft tissues 
(T3). It has not spread to nearby lymph nodes (N0) or to distant sites (M0).
or
T1 to T3, N1, M0: The tumor is any size and may have grown into nearby soft tissues (T1 to 
T3). The cancer has spread to one lymph node on the same side of the head or neck as the 
primary tumor, but the lymph node is no larger than 3 cm across (N1). The cancer has not 
spread to distant sites (M0).
Stage IVA: Either of the following:
T4a, N0 or N1, M0: The tumor is any size but has grown into nearby structures such as the jaw 
bone, skin, ear canal, and/or facial nerve (T4a). It may or may not have spread to one lymph 
node (no larger than 3 cm across) on the same side of the head or neck as the primary tumor 
(N0 or N1). The cancer has not spread to distant sites (M0).
or
T1 to T4a, N2, M0: The tumor is any size and may or may not have grown into nearby soft 
tissues or structures such as the jaw bone, skin, ear canal, and/or facial nerve (T1 to T4a). The 
cancer has spread to more than one lymph node, to a lymph node larger than 3 cm across, or 
to lymph nodes on the other or both sides of the neck. None of the lymph nodes are larger 
than 6 cm across (N2). The cancer has not spread to distant sites (M0).
Stage IVB: Either of the following:
T4b, Any N, M0: The tumor is any size and has grown into nearby structures such as the base 
of the skull or other bones nearby, or it surrounds the carotid artery (T4b). The cancer may or 
may not have spread to nearby lymph nodes (any N). It has not spread to distant sites (M0).
or
Any T, N3, M0: The tumor is any size and may or may not have grown into nearby soft tissues 
or other structures (any T). The cancer has spread to at least one lymph node that’s larger than 
6 cm across (N3). It has not spread to distant sites (M0).
Stage IVC: Any T, Any N, M1: The tumor is any size and may or may not have grown into 
nearby soft tissues or other structures (any T). The cancer may or may not have spread to 
nearby lymph nodes (any N). It has spread to distant sites (M1).
Salivary Gland Cancers: A Survey through History, Classifications and Managements
http://dx.doi.org/10.5772/intechopen.70127
47
Author details
Mohammad Hossein Khosravi1,2, Ali Bagherihagh2,4, Masoumeh Saeedi2,4, Payman 
Dabirmoghaddam5, Ali Kouhi2,3* and Mohammad Hosein Amirzade-Iranaq2,6
*Address all correspondence to: alikouhi@gmail.com
1 Student Research Committee (SRC), Baqiyatallah University of Medical Sciences, Tehran, 
Iran
2 International Otorhinolaryngology Research Association (IORA), Universal Scientific 
Education and Research Network (USERN), Tehran, Iran
3 Department of Otolaryngology-Head and Neck Surgery, Otorhinolaryngology Research 
Center, Tehran University of Medical Sciences, Tehran, Iran
4 Department of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medicine, Baqiatallah 
University of Medical Sciences, Tehran, Iran
5 Tehran University of Medical Sciences, Tehran, Iran
6 Student Research Committee, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
References
[1] Holmberg KV, Hoffman MP. Anatomy, biogenesis and regeneration of salivary glands. 
Ligtenberg AJM, Veerman ECI (eds). In: Saliva: Secretion and Functions. Vol. 24. Karger 
Publishers, Basel; 2014. pp. 1-13
[2] Johns M. The salivary glands: Anatomy and embryology. Otolaryngologic Clinics of 
North America. 1977;10(2):261
[3] Cate-Ten A. Oral Histology: Development, Structure, and Function. Saint Louis, Missouri: 
Mosby; 1998
[4] Tucker AS, editor. Salivary gland development. Seminars in cell & developmental biology. 
Elsevier: 2007 Apr;18(2):237-44. DOI:10.1016/j.semcdb.2007.01.006
[5] Speight P, Barrett A. Salivary gland tumours. Oral diseases. 2002;8(5):229-240
[6] Mendenhall WM, Werning JW, Pfister DG. Treatment of head and neck cancer. In: 
DeVita VT Jr, Lawrence TS, Rosenberg SA, editors. Cancer: Principles and Practice of 
Oncology. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2011. pp. 729-780
[7] Ellis GL, Auclair PL. Tumors of the salivary glands. atlas of tumor pathology, 3rd series, 
fascicle 17. Washington DC: Armed Forces Institute of Pathology; 1996
[8] Wahlberg P, Anderson H, Biörklund A, Möller T, Perfekt R. Carcinoma of the parotid 
and submandibular glands—A study of survival in 2465 patients. Oral Oncology. 
2002;38(7):706-713
Diagnosis and Management of Head and Neck Cancer48
[9] Del Signore AG, Megwalu UC. The rising incidence of major salivary gland cancer in the 
United States. Ear, Nose, & Throat Journal. 2017;96(3):E13
[10] Scanlon EF, Sener SF. Head and neck neoplasia following irradiation for benign condi-
tions. Head & Neck Surgery. 1981;4(2):139-145
[11] Van der Laan B, Baris G, Gregor RT, Hilgers F, Balm A. Radiation-induced tumours of 
the head and neck. The Journal of Laryngology & Otology. 1995;109(04):346-349
[12] Spiro RH, Thaler HT, Hicks WF, Kher UA, Huvos AH, Strong EW. The importance of 
clinical staging of minor salivary gland carcinoma. The American Journal of Surgery. 
1991;162(4):330-336
[13] Gooden E, Witterick IJ, Hacker D, Rosen IB, Freeman JL. Parotid gland tumours in 
255 consecutive patients: Mount Sinai Hospital’s quality assurance review. Journal of 
Otolaryngology. 2002;31(6)
[14] Theriault C, Fitzpatrick P. Malignant parotid tumors prognostic factors and optimum 
treatment. American Journal of Clinical Oncology. 1986;9(6):510-516
[15] Guzzo M, Andreola S, Sirizzotti G, Cantu G. Mucoepidermoid carcinoma of the salivary 
glands: Clinicopathologic review of 108 patients treated at the National Cancer Institute 
of Milan. Annals of Surgical Oncology. 2002;9(7):688-695
[16] Goode RK, Auclair PL, Ellis GL. Mucoepidermoid carcinoma of the major salivary 
glands. Cancer. 1998;82(7):1217-1224
[17] Parsons JT, Mendenhall WM, Stringer SP, Cassisi NJ, Million RR. Management of minor 
salivary gland carcinomas. International Journal of Radiation Oncology Biology Physics. 
1996;35(3):443-454
[18] Terhaard CH, Lubsen H, Van der Tweel I, Hilgers F, Eijkenboom W, Marres H, et al. 
Salivary gland carcinoma: Independent prognostic factors for locoregional control, 
distant metastases, and overall survival: Results of the Dutch head and neck oncology 
cooperative group. Head & Neck. 2004;26(8):681-693
[19] Vander Poorten VL, Balm AJ, Hilgers FJ, Tan IB, Loftus-Coll BM, Keus RB, et al. The 
development of a prognostic score for patients with parotid carcinoma. Cancer. 1999; 
85(9):2057-2067
[20] Eveson JW, Auclair P, Gnepp DR, et al. Tumours of the Salivary Glands. World Health 
Organisation Classification of Tumours Pathology and Genetics of Head and Neck 
Tumours. Lyon: IARC Press; 2005. pp. 212-215
[21] Al-Mamgani A, van Rooij P, Verduijn GM, Meeuwis CA, Levendag PC. Long-term out-
comes and quality of life of 186 patients with primary parotid carcinoma treated with 
surgery and radiotherapy at the Daniel den Hoed Cancer Center. International Journal 
of Radiation Oncology Biology Physics. 2012;84(1):189-195
[22] Vander Poorten V, Triantafyllou A, Thompson L, Bishop J, Hauben E, Hunt J, et al. 
Salivary acinic cell carcinoma: Reappraisal and update. European Archives of Oto-
Rhino-Laryngology. 2016;273(11):3511-3531
Salivary Gland Cancers: A Survey through History, Classifications and Managements
http://dx.doi.org/10.5772/intechopen.70127
49
[23] Vander Poorten VL, Hart AA, van der Laan BF, de Jong RJB, Manni JJ, Marres HA, et 
al. Prognostic index for patients with parotid carcinoma. Cancer. 2003;97(6):1453-1463
[24] Patel NR, Sanghvi S, Khan MN, Husain Q, Baredes S, Eloy JA. Demographic trends and 
disease-specific survival in salivary acinic cell carcinoma: An analysis of 1129 cases. The 
Laryngoscope. 2014;124(1):172-178
[25] Lewis JE, Olsen KD, Weiland LH. Acinic cell carcinoma. Clinicopathologic review. 
Cancer. 1991;67(1):172-179
[26] Neskey DM, Klein JD, Hicks S, Garden AS, Bell DM, El-Naggar AK, et al. Prognostic 
factors associated with decreased survival in patients with acinic cell carcinoma. JAMA 
Otolaryngology–Head & Neck Surgery. 2013;139(11):1195-1202
[27] Hoffman HT, Karnell LH, Robinson RA, Pinkston JA, Menck HR. National Cancer 
Data Base report on cancer of the head and neck: Acinic cell carcinoma. Head & Neck. 
1999;21(4):297-309
[28] Gomez DR, Katabi N, Zhung J, Wolden SL, Zelefsky MJ, Kraus DH, et al. Clinical and 
pathologic prognostic features in acinic cell carcinoma of the parotid gland. Cancer. 
2009;115(10):2128-2137
[29] Saku T, Hayashi Y, Takahara O, Matsuura H, Tokunaga M, Tokuoka S, et al. Salivary 
gland tumors among atomic bomb survivors, 1950-1987. Cancer. 1997;79(8):1465-1475
[30] Biron VL, Lentsch EJ, Gerry DR, Bewley AF. Factors influencing survival in acinic 
cell carcinoma: A retrospective survival analysis of 2061 patients. Head & Neck. 
2015;37(6):870-877
[31] Omlie JE, Koutlas IG. Acinic cell carcinoma of minor salivary glands: A clinicopathologic 
study of 21 cases. Journal of Oral and Maxillofacial Surgery. 2010;68(9):2053-2057
[32] Poorten VV, Hunt J, Bradley PJ, Haigentz M, Rinaldo A, Mendenhall WM, et al. 
Recent trends in the management of minor salivary gland carcinoma. Head & Neck. 
2014;36(3):444-455
[33] Vander Poorten V, Bradley PJ, Takes RP, Rinaldo A, Woolgar JA, Ferlito A. Diagnosis 
and management of parotid carcinoma with a special focus on recent advances in molec-
ular biology. Head & Neck. 2012;34(3):429-440
[34] Cheung RL, Russell AC, Freeman J. Does routine preoperative imaging of parotid 
tumours affect surgical management decision making? Journal of Otolaryngology--
Head & Neck Surgery. 2008;37(3)
[35] Eisele D, Kleinberg L, O’Malley B. Management of malignant salivary gland tumors. In: 
Harrison LB, Sessions RB, Hong KH, editors. Head and Neck Cancer: A Multidisciplinary 
Approach. 1st ed. Philadelphia-New York: Lippincott-Raven; 1999. 721-748
[36] Spiro R. Management of malignant tumors of the salivary glands. Oncology (Williston 
Park, NY). 1998;12(5):671-680; discussion 83
Diagnosis and Management of Head and Neck Cancer50
[37] Yousem DM, Kraut MA, Chalian AA. Major salivary gland imaging 1. Radiology. 
2000;216(1):19-29
[38] Li J, Gong X, Xiong P, Xu Q, Liu Y, Chen Y, et al. Ultrasound and computed tomography 
features of primary acinic cell carcinoma in the parotid gland: A retrospective study. 
European Journal of Radiology. 2014;83(7):1152-1156
[39] Jungehuelsing M, Sittel C, Fischbach R, Wagner M, Stennert E. Limitations of magnetic 
resonance imaging in the evaluation of perineural tumor spread causing facial nerve 
paralysis. Archives of Otolaryngology–Head & Neck Surgery. 2000;126(4):506-510
[40] Lee Y, Wong K, King A, Ahuja A. Imaging of salivary gland tumours. European Journal 
of Radiology. 2008;66(3):419-436
[41] Johnykutty S, Miller CH, Hoda RS, Giampoli EJ. Fine-needle aspiration of dedifferenti-
ated acinic cell carcinoma: Report of a case with cyto-histological correlation. Diagnostic 
Cytopathology. 2009;37(10):763-768
[42] Stanley RJ, Weiland LH, Olsen KD, Pearson BW. Dedifferentiated acinic cell (aci-
nous) carcinoma of the parotid gland. Otolaryngology—Head and Neck Surgery. 
1988;98(2):155-161
[43] Yoo IR, Jung C-K, Kim SH, Chung SK. F-18 FDG PET/CT findings of dedifferentiated 
acinic cell carcinoma. Clinical Nuclear Medicine. 2010;35(6):473-474
[44] Skálová A, Vanecek T, Sima R, Laco J, Weinreb I, Perez-Ordonez B, et al. Mammary ana-
logue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: 
A hitherto undescribed salivary gland tumor entity. The American Journal of Surgical 
Pathology. 2010;34(5):599-608
[45] Vander Poorten VL, Balm AJ, Hilgers FJ. Management of cancer of the parotid gland. 
Current Opinion in Otolaryngology & Head and Neck Surgery. 2002;10(2):134-144
[46] Coca-Pelaz A, Rodrigo JP, Triantafyllou A, Hunt JL, Rinaldo A, Strojan P, et al. Salivary 
mucoepidermoid carcinoma revisited. European Archives of Oto-Rhino-Laryngology. 
2015;272(4):799-819
[47] Goode RK, El-Naggar AK. Mucoepidermoid carcinoma. In: Barnes L, Eveson JW, 
Reichart P, Sidransky D, editors. World Health Organization Classification of Tumours. 
Pathology and Genetics of Head and Neck Tumours. Lyon: IARC Press; 2005. pp. 219-220
[48] Masson P, Berger L. Epitheliomas a double metaplasie de la parotide. Bulletin De 
l’Association Francaise Pour L’Etude Du Cancer. 1924;13:366-373
[49] Ellis GL, Auclair PL. Tumors of the Salivary Glands. Atlas of Tumor Pathology, 3rd 
Series, Fascicle 17. Washington, DC: Armed Forces Institute of Pathology; 1996. pp. 
39-57, 155-175, 452-454
[50] Spiro RH. Salivary neoplasms: Overview of a 35-year experience with 2,807 patients. 
Head & Neck Surgery. 1986;8(3):177-184
Salivary Gland Cancers: A Survey through History, Classifications and Managements
http://dx.doi.org/10.5772/intechopen.70127
51
[51] Eversole L. Mucoepidermoid carcinoma: Review of 815 reported cases. Journal of Oral 
Surgery (American Dental Association: 1965). 1970;28(7):490
[52] Yoshida EJ, García J, Eisele DW, Chen AM. Salivary gland malignancies in children. 
International Journal of Pediatric Otorhinolaryngology. 2014;78(2):174-178
[53] Melrose RJ, Abrams AM, Howell FV. Mucoepidermoid tumors of the intraoral minor 
salivary glands: A clinicopathologic study of 54 cases. Journal of Oral Pathology & 
Medicine. 1973;2(6):314-325
[54] Crain N, Nelson BL, Barnes EL, Thompson LD. Ceruminous gland carcinomas: A clini-
copathologic and immunophenotypic study of 17 cases. Head and Neck Pathology. 
2009;3(1):1-17
[55] Ferlito A, Recher G, Bottin R. Mucoepidermoid carcinoma of the larynx. A clinicopath-
ological study of 11 cases with review of the literature. ORL; Journal for Oto-Rhino-
Laryngology and Its Related Specialties. 1981;43:280-299
[56] Paulino AF, Huvos AG. Epithelial tumors of the lacrimal glands: A clinicopathologic 
study. Annals of Diagnostic Pathology. 1999;3(4):199-204
[57] Wolfish EB, Nelson BL, Thompson LD. Sinonasal tract mucoepidermoid carcinoma: A 
clinicopathologic and immunophenotypic study of 19 cases combined with a compre-
hensive review of the literature. Head and Neck Pathology. 2012;6(2):191-207
[58] Sharma P, Jain TK, Singh H, Suman SK, Faizi NA, Kumar R, et al. Utility of 18F-FDG 
PET-CT in staging and restaging of patients with malignant salivary gland tumours: A 
single-institutional experience. Nuclear Medicine Communications. 2013;34(3):211-219
[59] Adelstein DJ, Koyfman SA, El-Naggar AK, Hanna EY, editors. Biology and management 
of salivary gland cancers. Seminars in Radiation Oncology. 2012: Elsevier
[60] Garden AS, El-Naggar AK, Morrison WH, Callender DL, Ang KK, Peters LJ. 
Postoperative radiotherapy for malignant tumors of the parotid gland. International 
Journal of Radiation Oncology Biology Physics. 1997;37(1):79-85
[61] Chen AM, Lau VH, Farwell DG, Luu Q, Donald PJ. Mucoepidermoid carcinoma of the 
parotid gland treated by surgery and postoperative radiation therapy: Clinicopathologic 
correlates of outcome. The Laryngoscope. 2013;123(12):3049-3055
[62] Byrd SA, Spector ME, Carey TE, Bradford CR, McHugh JB. Predictors of recurrence 
and survival for head and neck mucoepidermoid carcinoma. Otolaryngology--Head and 
Neck Surgery. 2013;149(3):402-408
[63] Jarvis S, Giangrande V, Brennan P. Mucoepidermoid carcinoma of the tonsil: A very rare 
presentation. Acta Otorhinolaryngologica Italica. 2013;33(4):286
[64] Chen AM, Granchi PJ, Garcia J, Bucci MK, Fu KK, Eisele DW. Local-regional recurrence 
after surgery without postoperative irradiation for carcinomas of the major salivary 
glands: Implications for adjuvant therapy. International Journal of Radiation Oncology 
Biology Physics. 2007;67(4):982-987
Diagnosis and Management of Head and Neck Cancer52
[65] Ghosh-Laskar S, Murthy V, Wadasadawala T, Agarwal J, Budrukkar A, Patil N, et al. 
Mucoepidermoid carcinoma of the parotid gland: Factors affecting outcome. Head & 
Neck. 2011;33(4):497-503
[66] Chen AM, Garcia J, Lee NY, Bucci MK, Eisele DW. Patterns of nodal relapse after surgery 
and postoperative radiation therapy for carcinomas of the major and minor salivary 
glands: What is the role of elective neck irradiation? International Journal of Radiation 
Oncology Biology Physics. 2007;67(4):988-994
[67] Bjørndal K, Krogdahl A, Therkildsen MH, Overgaard J, Johansen J, Kristensen CA, et 
al. Salivary gland carcinoma in Denmark 1990-2005: A national study of incidence, site 
and histology. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral 
oncology. 2011;47(7):677-682
[68] Bradley PJ. Adenoid cystic carcinoma of the head and neck: A review. Current Opinion 
in Otolaryngology & Head and Neck Surgery. 2004;12(2):127-132
[69] Coca-Pelaz A, Rodrigo JP, Bradley PJ, Vander Poorten V, Triantafyllou A, Hunt JL, 
et al. Adenoid cystic carcinoma of the head and neck–An update. Oral Oncology. 
2015;51(7):652-661
[70] Dodd R, Slevin NJ. Salivary gland adenoid cystic carcinoma: A review of chemotherapy 
and molecular therapies. Oral Oncology. 2006;42(8):759-769
[71] Argyris PP, Pambuccian SE, Cayci Z, Singh C, Tosios KI, Koutlas IG. Lacrimal gland 
adenoid cystic carcinoma with high-grade transformation to myoepithelial carcinoma: 
Report of a case and review of literature. Head and Neck Pathology. 2013;7(1):85-92
[72] Azar T, Abdul-Karim FW, Tucker HM. Adenoid cystic carcinoma of the trachea. The 
Laryngoscope. 1998;108(9):1297-1300
[73] Gu F-M, Chi F-L, Dai C-F, Chen B, Li H-W. Surgical outcomes of 43 cases with adenoid 
cystic carcinoma of the external auditory canal. American Journal of Otolaryngology. 
2013;34(5):394-398
[74] Saraydaroglu O, Coskun H, Kasap M. Unique presentation of adenoid cystic carci-
noma in postcricoid region: A case report and review of the literature. Head and Neck 
Pathology. 2011;5(4):413-415
[75] Batsakis JG. Carcinomas of the submandibular and sublingual glands. Annals of 
Otology, Rhinology & Laryngology 198695:211-212
[76] Vander Poorten VL, Balm AJ, Hilgers FJ, Tan IB, Loftus-Coll BM, Keus RB, et al. Prognostic 
factors for long term results of the treatment of patients with malignant submandibular 
gland tumors. Cancer. 1999;85(10):2255-2264
[77] van Weert S, Bloemena E, van der Waal I, de Bree R, Rietveld DH, Kuik JD, et al. Adenoid 
cystic carcinoma of the head and neck: A single-center analysis of 105 consecutive cases 
over a 30-year period. Oral Oncology. 2013;49(8):824-829
Salivary Gland Cancers: A Survey through History, Classifications and Managements
http://dx.doi.org/10.5772/intechopen.70127
53
[78] Nascimento AG, Amaral ALP, Prado LAF, Kligerman J, Silveira TRP. Adenoid cystic 
carcinoma of salivary glands. A study of 61 cases with clinicopathologic correlation. 
Cancer. 1986;57(2):312-319
[79] Sequeiros SG, Rodrigo TJ, Llorente PJ, Suárez NC. Prognostic factors in adenoid cystic 
carcinoma of salivary glands. Acta Otorrinolaringologica Espanola. 2005;56(8):361-367
[80] Spiro RH, Huvos AG, Strong EW. Adenoid cystic carcinoma of salivary origin: A clini-
copathologic study of 242 cases. The American Journal of Surgery. 1974;128(4):512-520
[81] Vander Poorten VL, Balm AJ, Hilgers FJ, Tan IB, Keus RB, Hart AA. Stage as major long 
term outcome predictor in minor salivary gland carcinoma. Cancer. 2000;89(6):1195-1204
[82] Zvrko E, Golubović M. Laryngeal adenoid cystic carcinoma. ACTA Otorhinolaryngologica 
Italica. 2009;29(5):279
[83] Stell PM. Adenoid cystic carcinoma. Clinical Otolaryngology and Allied Sciences. 
1986;11:267-291
[84] Kokemueller H, Eckardt A, Brachvogel P, Hausamen J-E. Adenoid cystic carcinoma of the 
head and neck—A 20 years experience. International Journal of Oral and Maxillofacial 
Surgery. 2004;33(1):25-31
[85] Franchi A, Gallo O, Bocciolini C, Franchi L, Paglierani M, Santucci M. Reduced E-cadherin 
expression correlates with unfavorable prognosis in adenoid cystic carcinoma of sali-
vary glands of the oral cavity. American Journal of Clinical Pathology. 1999;111(1):43-50
[86] Biswas KD, Saha J, Sen I, Biswas G, Sinha R, Saha D, et al. Unusual presentations of ade-
noid cystic carcinoma in extra-salivary gland subsites in head and neck region: A case 
series. Indian Journal of Otolaryngology and Head & Neck Surgery. 2014;66(1):286-290
[87] Husain Q, Kanumuri VV, Svider PF, Radvansky BM, Boghani Z, Liu JK, et al. Sinonasal 
adenoid cystic carcinoma: Systematic review of survival and treatment strategies. 
Otolaryngology--Head and Neck Surgery. 2013;148(1):29-39
[88] Matsuzaki H, Yanagi Y, Hara M, Katase N, Asaumi J, Hisatomi M, et al. Minor salivary 
gland tumors in the oral cavity: Diagnostic value of dynamic contrast-enhanced MRI. 
European Journal of Radiology. 2012;81(10):2684-2691
[89] Jeong H-S, Chung MK, Son Y-I, Choi JY, Kim HJ, Ko YH, et al. Role of 18F-FDG PET/CT 
in management of high-grade salivary gland malignancies. Journal of Nuclear Medicine. 
2007;48(8):1237-1244
[90] Shen C, Xu T, Huang C, Hu C, He S. Treatment outcomes and prognostic features in 
adenoid cystic carcinoma originated from the head and neck. Oral Oncology. 2012;48(5): 
445-449
[91] Renehan AG, Gleave E, Slevin NJ, McGurk M. Clinico-pathological and treatment-related 
factors influencing survival in parotid cancer. British Journal of Cancer. 1999;80(8):1296
[92] Spiro RH, Armstrong J, Harrison L, Geller NL, Lin S-Y, Strong EW. Carcinoma of major 
salivary glands: Recent trends. Archives of Otolaryngology–Head & Neck Surgery. 
1989;115(3):316-321
Diagnosis and Management of Head and Neck Cancer54
[93] Ferlito A, Shaha AR, Rinaldo A, Mondin V. Management of clinically negative cervi-
cal lymph nodes in patients with malignant neoplasms of the parotid gland. ORL. 
2001;63(3):123-126
[94] Ferlito A, Barnes L, Myers EN. Neck dissection for laryngeal adenoid cystic carcinoma: 
Is it indicated? Annals of Otology, Rhinology & Laryngology. 1990;99(4):277-280
[95] Spiro RH. Distant metastasis in adenoid cystic carcinoma of salivary origin. The 
American Journal of Surgery. 1997;174(5):495-498
[96] Pederson AW, Salama JK, Haraf DJ, Witt ME, Stenson KM, Portugal L, et al. Adjuvant 
chemoradiotherapy for locoregionally advanced and high-risk salivary gland malig-
nancies. Head & Neck Oncology. 2011;3(1):31
[97] Dillon PM, Chakraborty S, Moskaluk CA, Joshi PJ, Thomas CY. Adenoid cystic carci-
noma: A review of recent advances, molecular targets, and clinical trials. Head & Neck. 
2016;38(4):620-627
[98] Seethala RR. Salivary gland tumors: Current concepts and controversies. Surgical 
Pathology Clinics. 2017;10(1):155-176
[99] Kazakov DV, Schaller J, Vanecek T, Kacerovska D, Michal M. Brooke-Spiegler syn-
drome: Report of a case with a novel mutation in the CYLD gene and different types of 
somatic mutations in benign and malignant tumors. Journal of Cutaneous Pathology. 
2010;37(8):886-890
[100] Muller S, Barnes L. Basal cell adenocarcinoma of the salivary glands: Report of seven 
cases and review of the literature. Cancer. 1996;78(12):2471-2477
[101] Zhan KY, Lentsch EJ. Basal cell adenocarcinoma of the major salivary glands: A 
 population-level study of 509 cases. The Laryngoscope. 2016;126(5):1086-1090
[102] Seethala RR, Barnes EL, Hunt JL. Epithelial-myoepithelial carcinoma: A review of the 
clinicopathologic spectrum and immunophenotypic characteristics in 61 tumors of 
the salivary glands and upper aerodigestive tract. The American Journal of Surgical 
Pathology. 2007;31(1):44-57
[103] Chiosea SI, Miller M, Seethala RR. HRAS mutations in epithelial–myoepithelial carci-
noma. Head and Neck Pathology. 2014;8(2):146-150
[104] Vázquez A, Patel TD, D’Aguillo CM, Abdou RY, Farver W, Baredes S, et al. Epithelial-
myoepithelial carcinoma of the salivary glands: An Analysis of 246 Cases. Otolaryngology-
-Head and Neck Surgery. 2015;153(4):569-574
[105] Chiosea SI, Griffith C, Assaad A, Seethala RR. The profile of acinic cell carcinoma after 
recognition of mammary analog secretory carcinoma. The American Journal of Surgical 
Pathology. 2012;36(3):343-350
[106] Chiosea SI, Griffith C, Assaad A, Seethala RR. Clinicopathological characteriza-
tion of mammary analogue secretory carcinoma of salivary glands. Histopathology. 
2012;61(3):387-394
Salivary Gland Cancers: A Survey through History, Classifications and Managements
http://dx.doi.org/10.5772/intechopen.70127
55

